A Phase I, Randomized, Open-Label, Single Center Study to Investigate the Effect of Formulation and Food on the Pharmacokinetics of GDC-0810 in Female Healthy Subjects on Non-Childbearing Potential
Phase of Trial: Phase I
Latest Information Update: 25 Aug 2017
At a glance
- Drugs Brilanestrant (Primary)
- Indications Breast cancer
- Focus Pharmacokinetics
- Sponsors Genentech
- 03 Apr 2017 Status changed from recruiting to completed.
- 04 May 2016 Planned End Date changed from 1 Mar 2018 to 1 Oct 2017.
- 04 May 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Oct 2017.